Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29950132 | 1.00 | ADORA2A (1.00) | ADORA2A | |
| SCHEMBL20658454 | 0.88 | ADORA2A (0.78) | ADORA2A | |
| SCHEMBL20667291 | 0.88 | ADORA2A (0.81) | ADORA2A | |
| SCHEMBL20658559 | 0.88 | ADORA2A (0.78) | ADORA2A | |
| SCHEMBL20666618 | 0.87 | ADORA2A (0.77) | ADORA2A | |
| SCHEMBL20666621 | 0.86 | ADORA2A (0.76) | ADORA2A | |
| SCHEMBL20666875 | 0.86 | ADORA2A (0.78) | ADORA2A | |
| SCHEMBL20666619 | 0.85 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL20667419 | 0.85 | ADORA2A (0.74) | ADORA2A | |
| SCHEMBL20667906 | 0.84 | ADORA2A (0.75) | ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230066315-A1 | COMPOUNDS AND USES THEREOF | NUVATION BIO OPERATING COMPANY LLC | 2023-03-02 | — | — | US | disclosed |
| US-20220298142-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2022-09-22 | — | — | US | disclosed |
| US-11306071-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2022-04-19 | — | — | US | disclosed |
| CN-113924095-A | Heterocyclic compounds as adenosine antagonists | 诺维逊生物股份有限公司 | 2022-01-11 | — | — | CN | disclosed |
| EP-3911322-A1 | COMPOUNDS AND USES THEREOF | Nuvation Bio Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-3911323-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | Nuvation Bio Inc. (US) | 2021-11-24 | — | — | EP | disclosed |
| CN-113613655-A | Compound and use thereof | 诺维逊生物股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | NUVATION BIO INC. (US) | 2021-06-08 | — | — | US | disclosed |
| WO-2020150675-A1 | COMPOUNDS AND USES THEREOF | NUVATION BIO INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2020-07-23 | — | — | US | disclosed |
| WO-2020150674-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020150674-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| EP-3654978-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | Nuvation Bio Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| CN-111163780-A | Heterocyclic compounds as adenosine antagonists | 诺维逊生物股份有限公司 | 2020-05-15 | — | — | CN | disclosed |
| WO-2019018584-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | GiraFpharma LLC (US) | 2019-01-24 | — | — | WO | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | SAGARD HOLDINGS MANAGER LP, AS ADMINISTRATIVE AGENT (CA) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11306071-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885 |
| US-20190023666-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885 |
| US-20230066315-A1 | COMPOUNDS AND USES THEREOF | ADORA2A, GRK2, GRK4 | ADORA2A 1/4885 |
| US-11028058-B2 | Heterocyclic compounds as adenosine antagonists | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885 |
| US-20200231570-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885 |
| US-20220298142-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.